secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0001367644-25-000019
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions Q4 loss narrows 37% to $31.3M; FY24 revenue $1.04B; guides FY25 EBITDA $150-200M
--------------------------------------------------------------------------------

- Q4 2024 total revenue $194.7M, down 30% YoY; net loss $31.3M vs. $49.5M loss in Q4 2023.
- FY 2024 total revenue $1.04B (flat YoY); net loss $190.6M vs. $760.5M loss; adjusted EBITDA $183.1M vs. ($22.3M) loss.
- FY 2025 guidance: revenue $750-850M; adjusted EBITDA $150-200M; segment adjusted gross margin 48-51%.
- NARCAN sales fell 41% in Q4; Smallpox MCM sales surged 565% on ACAM2000 exports; Anthrax MCM down 71%.
- Appointed CEO Joseph Papa; received ~$550M medical countermeasure awards; FDA approved ACAM2000 for mpox prevention.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764425000019/0001367644-25-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764425000019/ebs-20250303.htm
  HTML page:      https://secwatch.observer/filing/0001367644-25-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer